Oculis
Develops investigational therapies for neuro-ophthalmology and dry eye disease.
$12.21
After-hours close−0.01 (−0.08%)
At close$12.22(−1.69%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 35.20%Insiders —
Shares outstanding 57.17M · Float 37.03M · 64.8% free float
Institutions13F, as of Mar 31, 2026
57 holders · 20.12M shares · 23 new positions · 34 increased · 11 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Eqt Fund Management S.A R.L. | 5.90M | 10.32% | 0 | May 14, 2026 |
| 2.43M | 4.25% | −17.6K | Apr 14, 2026 | |
| Abrdn PLC | 1.75M | 3.06% | 0 | Apr 29, 2026 |
| Pivotal Bioventure Partners Investment Advisor LLC | 1.68M | 2.94% | −608.4K | May 14, 2026 |
| Wellington Management Group LLP | 1.35M | 2.35% | −10.5K | May 15, 2026 |
| Millennium Management LLC | 913.0K | 1.60% | +897.4K | May 15, 2026 |
| Adage Capital Partners GP, L.L.C. | 833.2K | 1.46% | +833.2Knew | May 15, 2026 |
| Sr One Capital Management, LP | 641.0K | 1.12% | 0 | May 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 11.80% | 6.95M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.